Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hannonen, P.
Right arrow Articles by Roponen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hannonen, P.
Right arrow Articles by Roponen, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 37, 1279-1286, Copyright © 1998 by British Society for Rheumatology

ORIGINAL PAPERS

A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder

P Hannonen, K Malminiemi, U Yli-Kerttula, R Isomeri and P Roponen
Department of Medicine, Central Hospital, Jyvaskyla, Finland.

OBJECTIVE: To study the usefulness of moclobemide and amitriptyline in the treatment of fibromyalgia (FM) in females without psychiatric disorder. METHODS: In the present four centre, 12 week study, 130 female FM patients not suffering from psychiatric disorders were randomized to receive amitriptyline (AMI; 25 37.5 mg), moclobemide (MOCLO; 450-600 mg) or identical placebo. RESULTS: Seventy-four, 54 and 49 per cent of patients on AMI, MOCLO and placebo, respectively, were judged as responders. The patients on AMI also managed best regarding the respective improvements during the trial in general health, pain, sleep quality and quantity, and fatigue on visual analogue scales (VAS), the areas of the Nottingham Health Profile (NHP), as well as in the three Sheehan's functional disability scales. In the within-group comparisons, MOCLO also improved pain assessed both on VAS and on the NHP pain dimension, but the improvement was invalidated by the poor success of the drug with regard to sleep. The tolerabilities of all three drugs were comparable. CONCLUSION: The study indicates that MOCLO may not be helpful in FM patients free from clinically meaningful psychiatric problems.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
W. Hauser, K. Bernardy, N. Uceyler, and C. Sommer
Treatment of Fibromyalgia Syndrome With Antidepressants: A Meta-analysis
JAMA, January 14, 2009; 301(2): 198 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. Nishishinya, G. Urrutia, B. Walitt, A. Rodriguez, X. Bonfill, C. Alegre, and G. Darko
Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy
Rheumatology, December 1, 2008; 47(12): 1741 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Perrot, R.-M. Javier, M. Marty, C. Le Jeunne, F. Laroche, and the CEDR (Cercle d'Etude de la Douleur en Rhumatol
Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies
Rheumatology, August 1, 2008; 47(8): 1117 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S F Carville, S Arendt-Nielsen, H Bliddal, F Blotman, J C Branco, D Buskila, J A P Da Silva, B Danneskiold-Samsoe, F Dincer, C Henriksson, et al.
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Ann Rheum Dis, April 1, 2008; 67(4): 536 - 541.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
D. Nutt, K. Demyttenaere, Z. Janka, T. Aarre, M. Bourin, P. L. Canonico, J. L. Carrasco, and S. Stahl
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure
J Psychopharmacol, July 1, 2007; 21(5): 461 - 471.
[Abstract] [PDF]

Home page
 PsychosomaticsHome page
J. W. Denninger, G. I. Papakostas, Y. Mahal, W. Merens, J. E. Alpert, A. A. Nierenberg, A. Yeung, and M. Fava
Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine
Psychosomatics, August 1, 2006; 47(4): 348 - 352.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
H. V. Krell, A. F. Leuchter, I. A. Cook, and M. Abrams
Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back Pain
Psychosomatics, October 1, 2005; 46(5): 379 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A Häkkinen, K Häkkinen, P Hannonen, and M Alen
Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: comparison with healthy women
Ann Rheum Dis, January 1, 2001; 60(1): 21 - 26.
[Abstract] [Full Text]

Home page
 Rheumatology (Oxford)Home page
S. Akkus, N. Delibas, and M. N. Tamer
Do sex hormones play a role in fibromyalgia?
Rheumatology, October 1, 2000; 39(10): 1161 - 1163.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.